BBO-11818 in Adult Subjects With KRAS Mutant Cancer

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

Trial Details

NCT ID
NCT06917079
Phase
PHASE1
Sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • BBO-11818
  • Pembrolizumab
  • Platinum chemotherapy (cisplatin or carboplatin)
  • Pemetrexed
  • Cetuximab
  • FOLFOX
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Sacramento, California, United States|38.58157,-121.4944
  • San Diego, California, United States|32.71571,-117.16472
  • San Francisco, California, United States|37.77493,-122.41942
  • New Haven, Connecticut, United States|41.30815,-72.92816

Key Eligibility Criteria

  • Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, …
  • Measurable disease by RECIST v1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
  • Life expectancy \>24 weeks

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →